Technology NetworksHorizon Discovery Introduces Whole Human Genome Arrayed Libraries to Support CRISPR Activation ScreeningTechnology NetworksHorizon Discovery, a global leader in the application of gene editing and gene modulation to deliver inspired … Continue reading
PharmaTimes |
EU clears first allogenic stem cell therapy
PharmaTimes TiGenix and Takeda’s Alofisel has become the first allogeneic stem cell therapy to be approved for use across the European Union. The therapy (previously referred to as Cx601) has been cleared to treat complex perianal fistulas in adult patients with … Stem cell therapy developers unaffected by Cha Biotech debacleKorea Biomedical Review Stem Cell Therapy Market Status and Trend: Top Key Players, Industry Dynamics, And Regional Scope 2022Healthcare Journal |
PharmaTimes |
EU clears first allogenic stem cell therapy
PharmaTimes TiGenix and Takeda’s Alofisel has become the first allogeneic stem cell therapy to be approved for use across the European Union. The therapy (previously referred to as Cx601) has been cleared to treat complex perianal fistulas in adult patients with … Stem cell therapy developers unaffected by Cha Biotech debacleKorea Biomedical Review Stem Cell Therapy Market Status and Trend: Top Key Players, Industry Dynamics, And Regional Scope 2022Healthcare Journal |
PharmaTimes |
EU clears first allogenic stem cell therapy
PharmaTimes TiGenix and Takeda’s Alofisel has become the first allogeneic stem cell therapy to be approved for use across the European Union. The therapy (previously referred to as Cx601) has been cleared to treat complex perianal fistulas in adult patients with … Stem cell therapy developers unaffected by Cha Biotech debacleKorea Biomedical Review Stem Cell Therapy Market Status and Trend: Top Key Players, Industry Dynamics, And Regional Scope 2022Healthcare Journal |
STAT |
Cancer immunotherapy implants get boost by Novartis licensing
STAT ancer immunotherapy 1 — the process of activating a patient’s own immune system to fight a tumor — is a booming field in drug development. But it faces certain hurdles. Fewer than a quarter of cancer patients benefit from leading drugs in the class … |